Poseida Therapeutics Inc (PSTX)
$2
Insights on Poseida Therapeutics Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 9.35M → 24.99M (in $), with an average increase of 62.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -31.77M → -23.99M (in $), with an average increase of 32.5% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 62.1%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 321.2%
Performance
- $2.00$2.16$2.00
0.0%
Downside
Day's Volatility :7.37%
Upside
7.37%
- $1.54$4.27$2.00
23.0%
Downside
52 Weeks Volatility :63.93%
Upside
53.16%
Returns
| Period | Poseida Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -28.42% | -0.7% | 0.0% |
6 Months | -12.45% | 6.6% | 0.0% |
1 Year | -15.35% | 3.7% | -1.5% |
3 Years | -76.22% | 14.0% | -21.8% |
Highlights
Market Capitalization | 195.9M |
Book Value | $1.08 |
Earnings Per Share (EPS) | -1.37 |
Wall Street Target Price | 14.0 |
Profit Margin | -190.76% |
Operating Margin TTM | -103.66% |
Return On Assets TTM | -25.87% |
Return On Equity TTM | -84.75% |
Revenue TTM | 64.7M |
Revenue Per Share TTM | 0.72 |
Quarterly Revenue Growth YOY | 148.70000000000002% |
Gross Profit TTM | -22.4M |
EBITDA | -123.9M |
Diluted Eps TTM | -1.37 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.67 |
EPS Estimate Next Year | -1.8 |
EPS Estimate Current Quarter | -0.39 |
EPS Estimate Next Quarter | -0.38 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 600.0%
Technicals Summary
Sell
Neutral
Buy
Poseida Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Poseida Therapeutics Inc | -33.33% | -12.45% | -15.35% | -76.22% | -86.71% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Poseida Therapeutics Inc | NA | NA | NA | -1.67 | -0.85 | -0.26 | NA | 1.08 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Poseida Therapeutics Inc | Buy | $195.9M | -86.71% | NA | -190.76% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
FMR Inc
14.87%Pentwater Capital Management LP
6.19%BlackRock Inc
5.21%SILVERARC CAPITAL MANAGEMENT, LLC
3.84%Vanguard Group Inc
3.00%Geode Capital Management, LLC
1.58%
Corporate Announcements
Poseida Therapeutics Inc Earnings
Poseida Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
poseida therapeutics, inc. is currently developing car-t and gene therapy products for cancer and orphan diseases. spinout of transposagen biopharmaceuticals early this year, poseida is also collaborating with j&j’s janssen to develop allogeneic car-t therapies against cancer. poseida boasts best-in-class genome engineering capabilities for effectively silencing target genes or inserting therapeutic genes and/or technologies. proprietary tools include piggybac™ dna modification system, nextgen™ crispr, xtn™ talen and footprint-free™ gene editing system, which are clean (synthetic and virus-free) and can be surgically precise. poseida aims to shuttle the first car-t and gene therapy product candidates into phase i clinical trials in early 2016. poseida is now hiring and searching for ambitious and motivated scientists desiring a fast-paced work environment with diverse research opportunities in the field of cellular and gene therapy.
Organization | Poseida Therapeutics Inc |
Employees | 330 |
CEO | Mr. Mark J. Gergen J.D. |
Industry | Health Technology |
